Real-world data on keytruda and opdivo for HPV throat cancer could shape future trials
NCT ID NCT06771674
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 662 patients with HPV-positive throat cancer that had spread or come back. Researchers wanted to see how patients were treated with pembrolizumab (Keytruda) or nivolumab (Opdivo), with or without chemotherapy, in real-world settings. The goal was to gather information on patient characteristics, treatment patterns, and outcomes to help design better clinical trials in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) and nivolumab (Opdivo), with or without chemotherapy
- What this could lead to
- If successful, this study could help design better future trials by comparing real-world outcomes with clinical trial data.
- What could go wrong
- This is an observational study, not a test of a new treatment. It only looks back at existing data, so it cannot prove what works best.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS-POSITIVE RECURRENT/METASTATIC OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less radiation be safer for throat cancer?
- Can a simple swab predict who needs less radiation?
- New drug combo aims to shrink oral cancers before surgery
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
- New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
- New pill-chemo combo takes on hard-to-treat cancers